{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-018467","form_type":"8-K","ticker":"AXSM","cik":"0001579428","company_name":"Axsome Therapeutics, Inc.","filed_at":"2023-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.496068+00:00","generated_at":"2026-06-15T13:18:22.842405+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Axsome Q1 2023: Auvelity sales $15.7M, total revenue $94.6M, net loss narrows to $11.2M","bullets":["Auvelity net product sales $15.7M in first full quarter; ~31,000 prescriptions, up 298% vs Q4 2022.","Total Q1 revenue $94.6M including $65.7M upfront from Sunosi ex-U.S. license to Pharmanovia; net loss $(11.2)M ($0.26/sh) vs $(39.6)M ($1.03/sh) a year ago.","Sunosi net sales $12.9M (U.S. $11.2M, int'l $1.7M); U.S. prescriptions up 13% YoY and 4% sequentially.","Amended Hercules term loan to $350M with reduced rate, extended maturity; cash $246.5M at March 31.","Pipeline milestones: AXS-12 Phase 3 narcolepsy topline Q2 2023; AXS-07 migraine NDA resubmission 2H 2023; AXS-14 fibromyalgia NDA submission Q4 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-018467","json":"https://secwatch.observer/filing/0000950170-23-018467.json","markdown":"https://secwatch.observer/filing/0000950170-23-018467.md","text":"https://secwatch.observer/filing/0000950170-23-018467.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1579428/000095017023018467/0000950170-23-018467-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1579428/000095017023018467/axsm-20230508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T13:18:22.842405+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4590732e786bc59efe5a48b606953a57508b2e7d","claim":"Axsome Therapeutics, Inc. reported the first quarter ended March 31, 2023 results: revenue $94.6 million, net income net loss of $11.2 million, EPS $(0.26) per share.","evidence_excerpt":"2023 Financial Results and Corporate Update Auvelity ® 1Q 2023 net product sales of $15.7 million Total 1Q 2023 net product sales of $28.6 million Total 1Q 2023 revenue of $94.6 million, including Sunosi ® ex-U.S. license agreement upfront payment Company to host conference call today at 8:00 AM Eastern NEW YORK, May 8, 2023 (GLOBE NEWSWIRE) -- Axsome","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1579428/000095017023018467/0000950170-23-018467-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Revenue","value":"$94.6 million"},{"label":"Net income","value":"net loss of $11.2 million"},{"label":"EPS","value":"$(0.26) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}